Argatroban
FDA-approved product (injectable, injection), marketed as Argatroban, Argatroban In 0.9% Sodium Chloride, Argatroban In Dextrose and 1 more.
- Registered studies
- 38
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Recurrent thrombophlebitis
- Thrombocytopenia
- Thrombotic disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Direct thrombin inhibitors
- FDA pharmacologic class
- Anti-coagulant; Direct Thrombin Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
38registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Argatroban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Argatroban Plus R-tPA for Acute Ischemic Stroke
NCT03740958 · start 2018-12-21
Registered record
- Registry ID
- NCT03740958
- Conditions
- Stroke
- Interventions
- rt-PA; Argatroban
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2018-12-21
- Completion
- 2022-01-30
- Enrolment
- 808
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStrokeInterventionrt-PA; ArgatrobanPhasePhase 4Registry statusCompletedArgatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）
NCT03506009 · start 2018-07-11
Registered record
- Registry ID
- NCT03506009
- Conditions
- Argatroban, Rt-PA
- Interventions
- Argatroban combined with rt-PA; rt-PA
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2018-07-11
- Completion
- 2018-11-13
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArgatroban, Rt-PAInterventionArgatroban combined with rt-PA; rt-PAPhasePhase 4Registry statusTerminatedArgatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke
NCT03552354 · start 2017-10-25
Registered record
- Registry ID
- NCT03552354
- Conditions
- Stroke, Ischemic
- Interventions
- Argatroban plus dual antiplatelet
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-10-25
- Completion
- 2019-01-08
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStroke, IschemicInterventionArgatroban plus dual antiplateletPhasePhase 4Registry statusCompletedSafety of Argatroban Infusion in Conduction Disturbances
NCT05740371 · start 2017-04-18
Registered record
- Registry ID
- NCT05740371
- Conditions
- Stable Coronary Artery Disease (CAD); Unstable Angina (Troponin Negative)
- Interventions
- Argatroban
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-04-18
- Completion
- 2021-05-06
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStable Coronary Artery Disease (CAD); Unstable Angina (Troponin Negative)InterventionArgatrobanPhasePhase 4Registry statusCompletedThromboprophylaxis After Surgery for Gynecologic Malignancy in China
NCT02935530 · start 2016-01
Registered record
- Registry ID
- NCT02935530
- Conditions
- Gynecologic Neoplasms; Venous Thromboembolism; Low Molecular Weight Heparin; Argatroban
- Interventions
- s-LMWH; LMWH; Argatroban
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-01
- Completion
- 2017-10
- Enrolment
- 315
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGynecologic Neoplasms; Venous Thromboembolism; Low Molecular Weight Heparin; ArgatrobanInterventions-LMWH; LMWH; ArgatrobanPhasePhase 3Registry statusCompletedSafety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke
NCT02448069 · start 2015-05
Registered record
- Registry ID
- NCT02448069
- Conditions
- Stroke; Cerebral Ischemia
- Interventions
- Argatroban
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-05
- Completion
- 2016-08
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStroke; Cerebral IschemiaInterventionArgatrobanPhasePhase 2Registry statusCompletedDirect Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
NCT01911624 · start 2013-01
Registered record
- Registry ID
- NCT01911624
- Conditions
- Staphylococcus Aureus Bacteraemia
- Interventions
- direct thrombin inhibition; enoxaparin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2016-07
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcus Aureus BacteraemiaInterventiondirect thrombin inhibition; enoxaparinPhasePhase 2Registry statusCompletedArgatroban in Critically Ill Patients With Heparin Resistance
NCT01734252 · start 2012-07-29
Registered record
- Registry ID
- NCT01734252
- Conditions
- Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance
- Interventions
- Argatroban
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-07-29
- Completion
- 2016-04-01
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAchievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin ResistanceInterventionArgatrobanPhasePhase 2Registry statusCompletedRandomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
NCT01464788 · start 2011-10
Registered record
- Registry ID
- NCT01464788
- Conditions
- Ischemic Stroke
- Interventions
- Low Dose Argatroban; High Dose Argatroban; rt-PA (alteplase)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2011-10
- Completion
- 2015-06-11
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIschemic StrokeInterventionLow Dose Argatroban; High Dose Argatroban; rt-PA (alteplase)PhasePhase 2Registry statusTerminatedSignificance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
NCT01246011 · start 2010-11
Registered record
- Registry ID
- NCT01246011
- Conditions
- Coronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 Antibody
- Interventions
- Argatroban and warfarin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2010-11
- Completion
- 2011-07
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 AntibodyInterventionArgatroban and warfarinPhasePhase 4Registry statusTerminatedArgatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
NCT01163604 · start 2010-08
Registered record
- Registry ID
- NCT01163604
- Conditions
- CVD
- Interventions
- Argatroban; non-argatroban treated group
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-08
- Completion
- 2014-08
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCVDInterventionArgatroban; non-argatroban treated groupPhasePhase 4Registry statusCompletedArgatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting
NCT01980316 · start 2010-04
Registered record
- Registry ID
- NCT01980316
- Conditions
- CVD
- Interventions
- Argatroban; non-argatroban treated group
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2013-07
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCVDInterventionArgatroban; non-argatroban treated groupPhasePhase 4Registry statusCompletedClinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
NCT00861692 · start 2009-04
Registered record
- Registry ID
- NCT00861692
- Conditions
- Heparin-induced Thrombocytopenia Type II
- Interventions
- argatroban
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-04
- Completion
- 2011-02
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeparin-induced Thrombocytopenia Type IIInterventionargatrobanPhasePhase 2Registry statusCompletedRetrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
NCT01304238 · start 2009-02
Registered record
- Registry ID
- NCT01304238
- Conditions
- Acute HIT II (Heparin-induced Thrombocytopenia Type II)
- Interventions
- lepirudin; danaparoid; argatroban; fondaparinux
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2009-02
- Completion
- 2010-01
- Enrolment
- 195
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute HIT II (Heparin-induced Thrombocytopenia Type II)Interventionlepirudin; danaparoid; argatroban; fondaparinuxPhaseNot recordedRegistry statusCompletedArgatroban Versus Lepirudin in Critically Ill Patients
NCT00798525 · start 2009-01
Registered record
- Registry ID
- NCT00798525
- Conditions
- Heparin Induced Thrombocytopenia (HIT)
- Interventions
- Argatroban; Lepirudin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2009-01
- Completion
- 2012-03
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeparin Induced Thrombocytopenia (HIT)InterventionArgatroban; LepirudinPhasePhase 4Registry statusTerminated